Methods for treating cholestasis
AssigneeMirum Pharmaceuticals, Inc.
InventorsThomas JAECKLIN, Alejandro DORENBAUM
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.
Claims21
-102. (canceled)
A method for treating cholestasis in a subject having elevated serum bile acids (sBA), comprising administering to the subject maralixibat, or a pharmaceutically acceptable salt thereof, wherein maralixibat, or the pharmaceutically acceptable salt thereof, is administered twice daily (BID) in an amount of from about 280 μg/kg to about 600 μg/kg per dose.
A method for treating pruritus in a subject, wherein the pruritus is caused by cholestasis, comprising administering to the subject maralixibat, or a pharmaceutically acceptable salt thereof, wherein maralixibat, or the pharmaceutically acceptable salt thereof, is administered twice daily (BID) in an amount of from about 280 μg/kg to about 600 μg/kg per dose.
Dependencies are inferred from the claim text.